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Background. Adenoviral gene therapy in liver trans-
plantation has many potential applications, but cur-
rent vector delivery methods to grafts lack efficiency 
and require high titers. In this study, we attempted to 
improve gene delivery efficacy using three different 
delivery methods to liver grafts with adenoviral vec-
tor encoding the LacZ marker gene (AdLacZ). 
Methods. AdLacZ was delivered to cold preserved rat 
liver grafts by: (1) continuous perfusion via the portal 
vein (portal perfusion), (2) continuous perfusion via 
both the portal vein and hepatic artery (dual perfu-
sion), and (3) trapping viral perfusate in the liver vas-
culature by clamping outflow (clamp technique). 
Results. Using lxl09 plaque-forming units of Ad-
LacZ (multiplicity of infection of 0.4), transduction 
rate in g-hr preserved liver grafts, determined by 
5-bromo-4-chromo-g-indolyl-f1-n-galactopyranoside 
staining and f1-galactosidase assay 48 hr after trans-
plantation, was best with clamp technique (21.5±2.7% 
5-bromo-4-chromo-3-indolyl-f1-n-galactopyranoside-
positive cells and 81.1±3.6 Ulg f1-galactosidase), fol-
lowed by dual perfusion (18.5±1.8%, 66.6±19.4 U/g) and 
portal perfusion (8.8±2.5%, 19.7±15.4 U/g). Further 
studies using clamp technique demonstrated a near-
maximal gene transfer rate of 30% at multiplicity of 
infection of 0.4 with prolonged cold ischemia to 18 hr. 
Transgene expression was stable for 2 weeks and 
slowly declined to 7.8±12.1 % at day 28. Lack of inflam-
matory response was confirmed by histopathological 
examination and liver enzymes. Transduction was se-
lectively induced in hepatocytes with nearly no extra-
hepatic transgene expression in the lung and spleen. 
Conclusions. The clamp technique provides a highly ef-
ficient viral gene delivery method to cold preserved liver 
grafts. This method offers maximal infectivity of adenovi-
ral vector with minimal technical manipulation. 
The introduction of functional genes into organ grafts be-
fore transplantation has been an attractive approach to mod-
ulate deleterious posttransplant events. The range of poten-
tial therapeutic applications includes amelioration or 
prevention of host versus graft immune reactions and reduc-
tion of graft ischemic and preservation injury. Effective gene 
therapy requires a reliable method of gene transfer that 
efficiently inserts target genes to the parenchymal and/or 
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nonparenchymal cells in grafts to produce required levels of 
proteins. Viral vectors, especially replication-defective ad-
enoviruses, have been favored because of their ability to 
readily infect nonproliferating cells. In contrast, retroviral 
vectors infect only proliferating cells. Although adenoviral-
mediated recombinant gene expression has been limited to a 
short period after gene transfer, this approach may provide 
advantages in modifying the critical early posttransplant 
period when intense immunological events and ischemic 
graft injury occur. 
Previous studies using adenoviral vectors have demon-
strated in vivo infectivity in experimental liver transplant 
settings by perfusing grafts with viral vectors (1-3). How-
ever, these ex vivo or in situ perfusion techniques required 
high viral titers (1-5 x 1010 plaque-forming units [pfu)) to 
induce effective viral infection, most likely as a result of the 
limited contact of viral particles with the graft vasculature 
and the resulting escape of the majority of viral vector from 
the graft. Prolonged incubation with viral vector has been 
shown to induce higher levels of viral infection to the liver, 
but efficiency remained low E~RM% infection at virus titer 
5x1010) (2). In addition, previous methods of ex vivo perfu-
sion have included a complicated circuit, which may not be 
suitable for clinical application, and increases the chance of 
mechanical graft injuries. 
In this study, we developed an improved gene delivery 
method in the liver transplant setting that allows near-max-
imal infectivity of adenoviral vector by trapping vector per-
fusate within the liver graft for the duration of the cold 
preservation period. We compared this new technique with 
two other gene delivery methods consisting of continuous 
viral vector perfusion via the portal vein alone or dual per-
fusion via the portal vein and hepatic artery. Several vari-
ables affecting transduction efficiency were analyzed: (1) ef-
fects of different viral titers, (2) incubation times, and (3) 
delivery techniques. Mter transduction, we examined peak 
and duration of gene expression, cell specificity, as well as 
the extent of damage to the liver as a result of viral infection. 
MATERIALS AND METHODS 
Viral Vector 
The El- and E3-deleted adenovirus, AdLacZ*, contains the f3-ga-
lactosidase gene under a cytomegalovirus (CMV) promoter (GenVec, 
* Abbreviations: AdLacZ, adenoviral vector encoding LacZ; CMV, 
cytomegalovirus; LR, lactated Ringer's; MOl, multiplicity of infection; 
pfu, plaque-forming unites); SOOT, serum aspartate aminotraosferase; 
SGPT, serum alanine aminotraosferase; UW, University of Wisconsin; 
X-gal, 5-bromo-4-chromo-3-indolyl-f3-D-galactopyraooside. 
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Inc., Rockville, MD) (4). AdLacZ was grown in human embryonic 
kidney (293) cells, which contain the complementary El region for 
virus growth. Virus was purified from infected 293 cells at 2 days 
after infection by three freeze-thaw cycles, followed by three succes-
sive bandings on CsCl gradients. Purified virus was dialyzed into 10 
mM Tris, 150 mM NaCI (pH 7.8) containing 10 mM MgCl2 and 3% 
sucrose and frozen at -80°C until required for use. The viral titers 
were determined by plaque-forming assay, and expressed as pfu. 
Orthotopic Liver Transplantation 
Male Lewis rats (LEW, RTl1), weighing 200-300 g, were pur-
chased from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and 
maintained in a laminar-flow, specific-pathogen-free atmosphere at 
the University of Pittsburgh. The basic techniques of liver harvest-
ing and orthotopic transplantation without hepatic artery recon-
struction were according to the method previously described by Ka-
mada et al. (5). Some modifications were made in this study to 
accommodate viral vector delivery as described below. 
Viral Vector Delivery to Liver Grafts 
Three different delivery methods were applied during a cold pres-
ervation period to examine the efficacy of infection. 
In group 1, portal perfusion, gene delivery to the liver graft was 
performed through continuous portal vein perfusion. The donor an-
imal was anesthetized with methoxyflurane, and the liver was 
flushed in situ with chilled lactated Ringer's (LR) solution via the 
aorta. The liver graft was skeletonized, removed, and placed in a 
perfusion circuit, which was connected to a nonpulsatile pump (Cole 
Parmer, Chicago, IL) with a total circuit volume of 15 ml. Viral vector 
delivery was performed by continuous perfusion of LR solution con-
taining AdLacZ via the portal vein at a flow rate of 2 mllmin for 30 
min at 4°C, with recirculation of the viral perfusate. After perfusion, 
the graft liver was stored in the same perfusate containing AdLacZ 
at 4°C for a total cold preservation period of 3 hr before transplan-
tation. 
In group 2, dual perfusion, gene delivery was performed simulta-
neously via the portal vein and hepatic artery. After the same donor 
procedure as group 1, the celiac axis was isolated and the splenic, left 
gastric, and gastroduodenal branches were identified and ligated. 
The excised liver graft underwent ex vivo viral vector delivery by 
simultaneous continuous portal and arterial perfusion with LR so-
lution containing AdLacZ for 30 min at 4°C, and recirculation of 
perfusate. Flow rates for the portal vein and hepatic artery (through 
the celiac axis) were 2 and 6 mllmin, respectively, using the same 
continuous perfusion circuit as group 1. The liver was then kept in a 
bath of the perfusate at 4°C for a total cold preservation period of 3 
hr. 
In group 3, clamp technique, the liver was incubated with viral 
vector using the modified simple cold storage method previously 
described for improved graft microvascular circulation (6). The 
donor liver was flushed in situ with University of Wisconsin (UW) 
solution through the aorta. After routine skeletonization, the iso-
lated liver graft was slowly perfused with a total of 6 ml of UW 
solution containing AdLacZ through the portal vein and hepatic 
artery in two stages. The initial infusion with 2 ml via the portal 
vein and 1 ml via the hepatic artery was flushed out, and vascular 
clamps were then placed on the supra- and infrahepatic inferior 
vena cava to trap subsequent perfusate within the liver. An ad-
ditional 2 ml of perfusate via the portal vein and 1 ml via the 
hepatic artery were infused into the liver, retaining the viral 
suspension in the liver vasculature. After visible expansion of the 
liver capsule was noted, the hepatic artery was ligated and the 
portal vein was clamped. The liver was kept in a bath of UW 
solution at 4°C for a total preservation period of 3 or 18 hr. Livers 
were flushed with cold LR solution immediately before transplan-
tation. The volume of additional infusion (3 mI), which was 
trapped within the liver vasculature, was calculated to be approx-
imately 40% of uninfused liver weight, as recommended by a 
previous publication (6). 
Experimental Design 
Effect of delivery methods on infection rate. Liver grafts in groups 
1-3 were perfused with lXI09 pfu of AdLacZ viral vector, giving a 
multiplicity of infection (MOl) of 0.4 (maximum of 40% infection), 
estimating 2.5Xl09 cells in the liver (lxl09 hepatocytes [7] and a 
similar number of nonparenchymal cells). Livers were transplanted 
after a total cold preservation time of 3 hr. Control liver grafts were 
perfused in the same manner, but without viral vector. All animals 
were killed 48 hr after transplant (n =3 for each group). The delivery 
method that provided the highest infectivity was selected for use in 
all following studies. 
Varied viral titer. Liver grafts in group 3 were perfused with 
lx108 (MOl 0.04), 2xl08 (MOl 0.08), or lx109 (MOl 0.4) pfu of 
AdLacZ and incubated for 3 hr at 4°C before transplantation (n=3 
for each viral titer). Animals were killed 48 hr after transplant. 
Evaluation of incubation time. To determine whether increased 
incubation time would improve viral infectivity, liver grafts in group 
3 were incubated for a total cold ischemia time of 3 or 18 hr at 4°C 
with either 2XI08 or lX109 pfu of AdLacZ before transplantation 
(n=3 for each incubation time). Animals were killed 48 hr after 
transplant. 
Duration of gene expression. Liver grafts in group 3 were perfused 
with 1 X 109 pfu of AdLacZ (MOl 0.4) and incubated for 18 hr at 4°C. 
After transplantation, animals were killed at 1, 2, 7, 14, and 28 days 
(n=3 for each time point) to examine the duration oftransduced gene 
expression in the liver. Control livers were perfused with UW solu-
tion without viral vector and samples were obtained 48 hr and 14 
days after transplantation. Blood samples (0.7 ml) were collected 
from the tail vein 6 and 12 hr postoperatively, and then on postop-
erative days 1, 2, 3,5,7, and 14 (n=4 each time point for experimen-
tal animals, n=3 each time point for controls). 
Sampling. At death, each liver graft was flushed with LR solution 
before sampling. Left, middle, and right liver lobes, spleen, and lung 
were fixed in formalin for routine histopathology, fixed in 2% para-
formaldehyde for immunohistochemical staining, or snap-frozen in 
liquid nitrogen for recombinant {3-galactosidase protein analysis. 
5-Bromo-4-chromo-3-indolyl-{3-D-galactopyranoside 
(X-Gal) Staining 
Liver samples fixed in 2% paraformaldehyde for 2 hr at 4°C were 
transferred to 30% sucrose and kept overnight at 4°C. Tissues were 
snap-frozen in OCT using a bath of isopentane immersed in liquid 
nitrogen, cut on a cryostat to 7 JLm thickness, and mounted on glass 
slides. X-Gal (Boehringer-Mannheim Biochemical, Indianapolis, IN) 
solution was applied to tissue sections, and slides were incubated in 
a humidified chamber at 37°C overnight. Cells expressing {3-galac-
tosidase turned blue in the presence of X-gal. Tissue nuclei were 
stained with propidium iodide for 30 sec at room temperature. The 
percentage of cells positive for X-gal staining was assessed by count-
ing the number of positively staining cells and the total number of 
nuclei at 20 X magnification. At rates of infection> 10%, the density 
of X-gal was too great to count individual cells. Therefore, infection 
rates in these samples were assessed at 20x magnification by mea-
suring the total cross-sectional area and the area occupied by posi-
tive staining cells with the assistance of a computer quantification 
program (Optimas; Optimas Co., Seattle, WA). Eighteen to 30 fields 
were assessed for each liver, with equal number offields for each lobe 
(right, middle, and left). 
Histopathology 
Formalin-fixed liver samples were embedded in paraffin and cut 
into 4-JLm-thick sections. Tissues were stained with hematoxylin and 
eosin, and slides were assessed for inflammation and tissue damage. 
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Liver Function Tests 
To assess hepatic function and cellular injury after gene transfer 
and preservation, serum aspartate aminotransferase (SGOT) and 
serum alanine aminotransferase (SGPT) From Group 3 and control 
animals were measured using the Opera clinical chemistry system 
(Bayer Co., Tarrytown, NY). 
Recombinant Protein Detection 
{3-Galactosidase activity was determined using a {3-galactosidase 
enzyme assay kit (Promega, Madison, WI). Briefly, samples from the 
middle lobe of livers were homogenized and total protein was ex-
tracted by incubation with a reporter lysis buffer. Liver protein was 
incubated with o-nitrophenyl-{3-D-galactopyranoside at 37°C for 30 
min. Optical density of the solution was read at 420 nm, and com-
pared to a standard curve generated from known amounts ofrecom-
binant {3-galactosidase. Liver graft {3-galactosidase activity was re-
corded as units (U) of {3- galactosidase activity per gram (g) of total 
cellular protein. 
Analysis of Cells Expressing Transferred Gene 
A portion ofliver sample infected with AdLacZ was separated into 
hepatocyte and nonpal"enchymal cell fractions according to the 
method previously described (8) . Briefly, liver tissue was digested 
with L-15 medium containing 0.1% collagenase (Boehringer-Mann-
heim) and 0.005% trypsin inhibitor (Sigma Chemical, St. Louis, MO) 
at 37°C. Cell suspension was centrifuged at 400 rpm for 1 min and 
the pellet collected to isolate hepatocytes. Supernatant was centri-
fuged at 1200 rpm for 8 min to isolate nonparenchymal cells. After a 
brief red blood cell lysis step, debris from the non parenchymal cell 
fraction was removed by centrifugation at 2000 rpm for 30 min using 
a 30% Percoll (Sigma) gradient. Hepatocyte and nonparenchymal 
cell fractions were fixed with 2% para formaldehyde for 10 min and 
resuspended in X-gal staining solution. Cells were incubated at 37°C 
overnight. Cytospins were made, and cells analyzed for X-gal posi-
tivity. 
Statistical Analysis 
Results of infection rates and {3-galactosidase activity are ex-
pressed as the mean :!: standard deviation of the mean. Group 
comparisons were performed using ANOVA (analysis of variance) 
test. Differences were considered significant at P<0.05. 
RESULTS 
Effect of delivery methods on infection rate. The evaluation 
of different methods of gene delivery using a viral titer of 
Ix 109 pfu revealed substantial differences in viral infectivity 
between groups 1, 2, and 3 by X-gal staining (Fig. 1). As 
shown in Figure lA, control livers did not stain positive for 
X-gal. Portal perfusion alone (group 1) gave a transduction 
rate of 8.8::'::2.5% (Fig. 1B). Dual perfusion of the portal vein 
and hepatic artery (group 2) yielded a 18.5::':: 1.8% transduc-
tion rate (Fig. Ie), whereas the clamp technique (group 3) 
provided the greatest delivery at 21.5::'::2 .7% (Fig. 1D). The 
number of LacZ gene-transferred cells was significantly in-
creased in group 2 (P< 0 .005) and group 3 (P< O.OOl) animals , 
compared to that in group 1. Gene transfer was predomi-
nantly seen in liver cells near the portal triads in groups 1 
and 2 animals, whereas it was more dispersed through the 
entire liver lobes in group 3 animals. Results obtained from 
the f3-galactosidase enzyme assay (Fig. 2) independently con-
firmed X-gal staining data. Group 1 animals demonstrated 
an enzyme activity of 19 .7::'::15A U/g, whereas activity in-
creased 3-fold to 66.6::':: 19A U/g (P=0 .002 vs. group 1) in 
group 2, and was highest at 81.1::'::3.6 U/g in group 3 
FIGURE l. X-Gal staining of liver tissue 48 hr after transduction 
with I x 109 pfu of AdLacZ by different gene delivery methods (orig-
inal magnification , x 10). (A) Control animals demonstrated no pos-
itive staining; (B) portal perfusion in group 1 yielded a 9% transduc-
tion rate (dark cells); (C) dual perfusion in group 2 demonstrated 
twice as many positive cells at 18%; CD) clamp technique in group 3 













FIGURE 2. Comparison of methods of delivery by {3-galactosidase 
enzyme assay confirms the superior transduction rates using the 
dual perfusion (group 2) and clamp technique (group 3) compared to 
portal perfusion (group 1) 48 hr after 1 X 109 pfu of AdLacZ delivery. 
*, P <O.Ol vs. group l. 
(P=0.008 vs. group 1, NS vs. group 2). Although similar 
transduction rates were seen with the dual perfusion and 
clamp techniques, less technical manipulation was required 
in the clamp technique of gene delivery. Accordingly, the 
clamp technique was then used in further experiments to 
study other variables affecting gene transduction. 
Effect of viral titer on gene delivery. Similar to the previ-
ous report by Shaked et al. (2) using the portal infusion 
technique, a clear positive correlation between viral titer and 
transduction rate of liver cells was observed with the clamp 
technique in group 3 animals. With infusion of I x 108 pfu of 
AdLacZ (MOI=0.04), the gene transfer rate was 3.9::'::0.7%. 
By using higher viral titers of 2 X 108 pfu (MOI=0.08) and 
I x 109 pfu (MOI=OA), the percentage of liver cells positive 
for LacZ increased to 6.2::':: 1.7% and 21.5::'::2.7%, respectively. 
Evaluation of incubation time. Inasmuch as the cold isch-
emia time of liver grafts in the clinical setting often varies 
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FIGURE 3. Percentages of LacZ-positive cells in group 3 livers incu-
bated for 3 or 18 hr with 2xl0B or lxl09 pfu of AdLacZ. Figure 
shows percentages 48 hr after transplantation. *, P<O.OI vs. 3-hr 
incubation. 
from 3 hr to 20 hr, we evaluated the effect of different incu-
bation times (cold ischemia time) on gene delivery. Group 3 
livers incubated with 2 X 108 pfu of viral vector for a total cold 
ischemia time of 3 or 18 hr demonstrated 6.2::':::1.7% and 
5.2::':::1.3% infectivity, respectively (Fig. 3). When increasing 
the viral titer to 1X109, livers incubated for 3 hr showed 
21.5±2.7% positive for LacZ, and prolonging cold ischemia 
time to 18 hr resulted in a significant increase in positive 
staining to 29.9::':::5.1% (P<O.Ol vs. 3-hr incubation). As the 
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FIGURE 4. Time course of transgene expression after lxl09 pfu of 
AdLacZ delivery by clamp technique (18-hr incubation). (A) Percent-
ages of LacZ·positive cells; (B) J3-galactosidase enzyme assay. 
40%, these results demonstrate that near-maximal transduc-
tion is obtained by using this gene delivery method. 
Duration of gene expression. To determine the duration of 
transgene expression in the liver grafts, we performed a 
posttransplant time-course study. When the liver was in-
fected with 1 x 109 pfu of AdLacZ for the 18 hr incubation 
period, a constant gene transfer rate near 30% was main-
tained at 1, 2, 7, and 14 days after transplant (Fig. 4A). At 
day 28 after transplant, the percentage of positive staining 
decreased to 7.8±12.1%, with considerable variability be-
tween different animals. Recombinant protein analysis con-
firmed a stable level of l3-galactosidase activity at roughly 
100 Dig through day 14 (Fig. 4B). This value decreased to 
40.2 ± 49.4 Dig by day 28 after transplant. 
Liver injury. AI; adenovirus has been reported to induce an 
inflammatory reaction in situ (9), we examined the effect of 
virus delivery on liver enzymes and histopathology. Serum 
SGOT and SGPT levels peaked 12-24 hr after transplant in 
group 3 and control animals (Fig. 5, A and B). Liver enzymes 
returned to normal values by day 3 after transplant, and 
remained low through 14 days. These results demonstrate 
that no liver damage was induced by LacZ transduction. 
Histopathological examination of the liver grafts revealed 
spotty necrosis in both group 3 and control livers at 48 hr 
after transplant. At days 14 and 28, liver grafts demon-
strated normal appearance. No inflammatory infiltrate was 
noted in either LacZ-infected or control animals throughout 
the course of the study. 
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FIGURE 5. Changes in serum SGOT CA) or SGPT (B) levels after 
lxl09 pfu of AdLacZ delivery by clamp technique Cl8-hr incubation). 
Control animals received liver grafts not perfused with AdLacZ. 
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Analysis of cells expressing transferred gene. To determine 
which liver cell types were being infected by the adenovirus, 
we isolated hepatocyte and non parenchymal cell fractions 
from transfected livers . After isolation and X-gal staining of 
the two fractions, a clear difference in positivity was noted 
among cell types (Fig. 6, A and B). Positive cells were abun-
dantly found in the hepatocyte fraction , whereas few positive 
cells « 1 %) could be observed in the non parenchymal cell 
fraction, suggesting that the AdLacZ selectively targets 
hepatocytes in the liver. 
Escape of vector to extrahepatic organs. To determine if 
the targeted gene delivery remained organ-specific, we 
stained additional organs for LacZ expression. Few cells E~1 
per section) in the lung and spleen were found to be positive 
for LacZ gene expression with X-gal staining (Fig. 6, C and 
D). This lack of expression in extrahepatic organs suggests 
that the viral vector specifically targets hepatocytes using 
our delivery method. 
DISCUSSION 
This study demonstrates a highly efficient in vivo gene 
transfer method, which allows maximal infectivity of ad-
enoviral vector to liver grafts. The procedure is simple, 
does not require extra instrumentation, and is clinically 
applicable. In previous studies, gene delivery to 10-30% 
cells in rat liver was obtained only when very high titers of 
adenoviral vector (5 X 1010 pfu) was delivered via portal 
perfusion (1, 2). These titers correspond to an MOl of 20, 
based on the estimated total number of rat liver cells as 
2.5 X 109 (7), suggesting that the majority of infused vector 
fails to infect liver cells. Using the delivery method de-
scribed here, similar infectivity is achieved with substan-
tially lower titer of viral vector (IX 109 pfu, 50-fold less) . 
This infectivity, at an MOl of 0.4, was near a theoretical 
maximum transduction rate of 40%. The superiority of this 
delivery method compared to previous studies is based on 
the following: (1 ) vector infusion via both the portal vein 
and hepatic artery allows delivery of viral vector to areas 
of hepatic microcirculation that were inaccessible by single 
perfusion, likely as a result of vasoconstriction caused by 
cold preservation; (2) vector-target cell contact is enhanced 
by trapping of vectors in the liver microcirculation; and (3) 
longer incubation of vector in the graft microvasculature 
can be achieved for the cold preservation period to further 
enhance gene transduction. As the conventional perfusion 
method may be difficult to apply in a clinical setting, the 
clamp technique, which involves less technical difficulty 
and instrumental complexity, can readily be applied to a 
clinical transplant situation. 
As has been demonstrated previously, and now shown in 
our study. a proportionally larger percentage of liver cells 
could be transfected by increasing the MOl (2). Using the 
method described here. transduction efficiency at each suc-
cessive viral titer reaches near-maximal infectivity. 
Although it has been widely used for gene therapy. a major 
disadvantage of the adenovirus vector has been the low level 
production of viral late proteins and the subsequent host 
immune responses against these protein antigens. These in-
FIGURE 6. X-Gal staining of hepatocyte (A) and nonparenchymal cell (B) fractions. A large number of hepatocytes stained positive with X-gal, 
whereas only a few were positive in the non parenchymal cell fraction. Positive cells were scarcely found in the lung (C) or spleen (D). Figure shows 
lXl09 pfu of AdLacZ, 48 hr after transplant. Original magnification, x 20. 
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duce local inflammation, destruction of transduced cells, and 
formation of adenoviral vector-specific antibodies, resulting 
in the limited persistence of trans gene expression, as well as 
the inability to repeat vector administration. These conse-
quences were delineated in previous rodent studies involving 
liver transduction by adenoviral vectors infused into the he-
patic or systemic circulation (9-11), and have led to the 
recent development of second generation adenovirus vectors, 
which contain additional deletions of early transcription 
units (12, 13). LacZ expression in our study started to decline 
3-4 weeks after delivery. However, we did not observe he-
patic inflammatory infiltrates or liver-related enzyme eleva-
tion, which have been shown to be associated with disappear-
ance of transgene expression (13, 14). 
The explanation for a lack of inflammatory response in this 
study is not entirely clear. Interestingly, Olthoff and co-
workers (15) have recently observed similar findings in rat 
liver grafts after ex vivo perfusion of adenoviral vectors 
through the portal vein. This contrasts with the significant 
inflammatory response described after transduction of mu-
rine hepatocytes (10, 11), suggesting a species-specific re-
sponse. These murine studies utilized in vivo systemic deliv-
ery of viral vector, with significant exposure of recipient 
lymphoid tissues to the virus. In contrast, transduction using 
the current ex vivo method was limited almost exclusively to 
hepatocytes, with minimal transgene expression in liver non-
parenchymal cells and extrahepatic tissues, such as the lung 
and spleen. An immune response is based on a balance be-
tween potentially reactive lymphocytes and the composition, 
quantity, kinetics, and distribution of antigen within the host 
(16). Antigens that do not enter organized lymphoid tissues 
have been shown not to induce immune responses (immune 
indifference) (16), and viruses persisting in peripheral non-
lymphoid tissues, such as hepatocytes in this study, may be 
ignored by the host immune system. Leakage of antigens into 
lymphoid tissues in murine studies may contribute to the 
activation of T cells to control infection (9). 
The actual cause for the eventual loss of transgene expres-
sion despite the lack of a significant host inflammatory re-
sponse against the virus is unknown. Others have shown 
that the CMV promoter becomes silent in a few weeks after 
gene transfer in a number of animal studies including immu-
nocompetent and immunocompromised animals (17-19), ret-
roviral (18, 20) and adenoviral (21) vectors, and different cell 
types (20, 21). Loser et a1. (22) recently reported transcrip-
tional inactivation of the CMV promoter in the mouse liver 
after adenoviral transduction, probably through the inacti-
vation of the transcription factor NFKB. Whether this mech-
anism is occurring in the transplanted livers is uncertain, 
but it is at least possible that CMV promoter silencing may 
be in part responsible for loss of trans gene expression in our 
experiment. 
In summary, we have developed a method of gene delivery 
that allows near-maximal gene transfer efficiency to cold 
preserved liver grafts. Using the clamp technique, stable 
gene expression can be attained through 2 weeks after trans-
plant, allowing future therapeutic genes to target the critical 
early posttransplant period. This technique allows the use of 
substantially lower particles of adenoviral vector than previ-
ously established methods of vector delivery, and is not as-
sociated with an inflammatory response to the virus. Studies 
are currently under way to determine the effectiveness of this 
technique of gene delivery using potentially therapeutic func-
tional transgenes. 
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